spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Antiplatelet Agent 

 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 16 Feb 2016
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 23 Oct 2015
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2015
The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(R) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Dec 2013
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Aug 2013
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
Diagnostics Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology
 HSMN NewsFeed - 19 Dec 2012
Regado Biosciences, Inc. Secures $51 Million Series E Financing
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution
 HSMN NewsFeed - 9 Mar 2011
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
Diagnostics Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 16 Nov 2010
Mortality Data Presented for Patients Treated with Effient(R) Who Underwent Isolated Coronary Artery Bypass Surgery
Biopharmaceuticals Cardiology Surgery
 HSMN NewsFeed - 16 Nov 2010
GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI
Diagnostics Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 15 Mar 2010
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCI
Biopharmaceuticals Diagnostics Cardiology
 HSMN NewsFeed - 5 Jan 2010
New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 17 Dec 2009
Regado Biosciences, Inc. Completes $40 Million Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Nov 2009
AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Nov 2009
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Aug 2009
The Medicines Company Responds to Incorrect News Reports
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Jul 2009
The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2009
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 May 2009
Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 21 May 2009
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Apr 2009
World-First Launch of New Heart Drug
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 12 Mar 2009
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Feb 2009
Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
Devices Diagnostics Personnel
 HSMN NewsFeed - 26 Feb 2009
The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Feb 2009
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Feb 2009
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Jan 2009
The Medicines Company to Acquire Targanta Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Jan 2009
Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Dec 2008
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Nov 2008
Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 30 Oct 2008
Timothy I. Still Appointed CEO at Accumetrics
Diagnostics Personnel
 HSMN NewsFeed - 25 Sep 2008
Anthony Arnerich Appointed Executive Chairman at Accumetrics
Diagnostics Personnel
 HSMN NewsFeed - 3 Sep 2008
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2008
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jul 2008
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2008
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 5 Mar 2008
New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 4 Feb 2008
Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Nov 2007
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Oct 2007
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 2 Sep 2007
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Feb 2007
FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 16 Jan 2007
Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients With Acute Coronary Syndrome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2006
New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Oct 2006
The Medicines Company Commences Phase III Clinical Trial of Cangrelor
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 7 Sep 2006
European commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
Biopharmaceuticals Cardiology Regulatory
Return to NewsFeed  

 Additional items found! 26

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 26 additional stories matching:
Antiplatelet Agent
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!